OMX Nordic 40
2 341,43
|
-6,40
|
-0,27 %
|
Analysen zu OMX Nordic 40-Werten
20.11.24 | AstraZeneca Neutral | UBS AG | |
19.11.24 | Hennes & Mauritz AB Sell | Goldman Sachs Group Inc. | |
19.11.24 | Volvo AB Neutral | UBS AG | |
18.11.24 | Novo Nordisk Neutral | UBS AG | |
15.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
14.11.24 | Volvo AB Neutral | JP Morgan Chase & Co. | |
14.11.24 | A.P. Moeller - Maersk A-S Neutral | Goldman Sachs Group Inc. | |
13.11.24 | AstraZeneca Halten | DZ BANK | |
13.11.24 | AstraZeneca Hold | Deutsche Bank AG | |
13.11.24 | Novo Nordisk Neutral | UBS AG | |
13.11.24 | Hennes & Mauritz AB Buy | UBS AG | |
13.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
12.11.24 | AstraZeneca Hold | Jefferies & Company Inc. | |
12.11.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
12.11.24 | AstraZeneca Sell | UBS AG | |
12.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
12.11.24 | ABB Neutral | JP Morgan Chase & Co. | |
11.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
11.11.24 | Novo Nordisk Neutral | UBS AG | |
11.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
11.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
08.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
08.11.24 | Novo Nordisk Overweight | Barclays Capital | |
07.11.24 | Novo Nordisk Neutral | UBS AG | |
07.11.24 | Novo Nordisk Halten | DZ BANK | |
07.11.24 | Novo Nordisk Buy | Deutsche Bank AG | |
07.11.24 | AstraZeneca Sell | UBS AG | |
07.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
06.11.24 | Novo Nordisk Neutral | UBS AG | |
06.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
06.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
06.11.24 | Novo Nordisk Neutral | UBS AG | |
06.11.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
06.11.24 | AstraZeneca Hold | Deutsche Bank AG | |
06.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
05.11.24 | AstraZeneca Sell | UBS AG | |
05.11.24 | AstraZeneca Sell | Deutsche Bank AG | |
05.11.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
05.11.24 | Hennes & Mauritz AB Outperform | RBC Capital Markets | |
05.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. |